Effect of method of preparation on pioglitazone HCl-β-cyclodextrin inclusion complexes

Article Sidebar

PDF
Published: Aug 27, 2014
DOI: https://doi.org/10.22377/ajp.v4i2.142

Main Article Content

Shrikant P Beloshe
Dhanyakumar D Chougule
Rohit R Shah
Dhananjay S Ghodke
Nagnath D Pawar
Rahul P Ghaste

Abstract

Pioglitazone HCl is an antidiabetic agent with poor aqueous solubility. Inclusion complexes of pioglitazone HCl were prepared with β-cyclodextrin using various methods (physical mixing, kneading method, co-precipitation). The main
aim of the present invention is to study the effect of the method of preparation on the dissolution profiles of pioglitazone HCl-β-Cyclodextrin inclusion complexes. The phase solubility profile of pioglitazone HCl with β-cyclodextrin was classified
as AL-type and stability constant with 1:1 molar ratio was 115.45, calculated from the phase solubility diagram. Formation of the inclusion complex between pioglitazone HCl and β-cyclodextrin was confirmed by the Fourier Transform Infrared (FT- IR) spectroscopy. The dissolution profile of inclusion complexes were determined and compared with those of pioglitazone HCl alone and its physical mixtures.The dissolution rate of the pioglitazone HCl-β-cyclodextrin inclusion complex prepared by the co-precipitation method was six times higher when compared with the pure drug. The method of complexation of
pioglitazone HCl in β-CD increased the dissolution rate of the drug in the following order: Coppt > KM > PM >Drug.

Downloads

Download data is not yet available.

Article Details

How to Cite
Beloshe, S. P., Chougule, D. D., Shah, R. R., Ghodke, D. S., Pawar, N. D., & Ghaste, R. P. (2014). Effect of method of preparation on pioglitazone HCl-β-cyclodextrin inclusion complexes. Asian Journal of Pharmaceutics (AJP), 4(2). https://doi.org/10.22377/ajp.v4i2.142
Issue
Vol. 4 No. 2 (2010): Apr-June
Section
Articles

This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.

References

Rao VM, Nerurkar M, Pinnamaneni S, Rinaldi F, Raghavan K.

Co-solubilization of poorly soluble drugs by micellization and

complexation. Int J Pharm 2006;319:98-106.

Thorsteinn L, Marcus E, Mar M. Role of cyclodextrins in improving oral

drug delivery. Am J Drug Deliv 2004;2:1-15.

Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers.

Adv Drug Deliv Rev 2007;59:645-66.

Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An

updated review. AAPS PharmSciTech 2005;6:E329-57.

Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins

modify drug release from polymeric drug delivery systems. Int J Pharm

;197:1-11.

Cal K, Centkowska K. Use of cyclodextrins in topical formulations:

Practical aspects. Eur J Pharm Biopharm 2008;68:467-78.

Braibanti A, Fisicaro E, Ghiozzi A, Compari C, Bovis G. Host-guest

interactions between β-cyclodextrin and piroxicam. React Funct Polym

;36:25l-5.

Rai AK, Rai DK. Spectroscopic studies of some antidiabetic drugs.

Spectrochim Acta A Mol Biomol Spectrosc 2003;59:1673-80.

Khalil R, Elbary A, Kassem M, Samra M. Formulation and hypoglycemic

activity of pioglitazone-cyclodextrin inclusion complexes. Drug Discov

Ther 2008;2:94-107.

Waleczek KJ, Marques HM, Hempel B, Schmidt PC. Phase solubility

studies of pure (-)-alpha-bisabolol and camomile essential oil with

beta-cyclodextrin. Eur J Pharm Biopharm 2003;55:247-51.

Bhosale A, Hardikar S, Jagtap R, Patil, Dhawale S. Formulation of

β-cyclodextrin complexed controlled release matrix tablets of glipizide

and its in-vitro evaluation. Int J PharmTech Res 2009;1:773-8.

Higuchi T, Connors K. Phase-solubility techniques. Adv Anal Chem

Instrum 1965;4:117-212.

Vij M, Garse H, Dand N, Kadam V, Hirlekar R. Effect of preparation

method on complexation of cefdinir with β-cyclodextrin. J Incl Phenom

Macrocycl Chem 2009;11:1-9.

Sapkal N, Kilor V, Bhusari K, Daud A. Evaluation of some methods for

preparing gliclazide-β-cyclodextrin inclusion complexes. Trop J Pharm

Res 2007;6:833-40.

Karthik A, Subramanian G, Rao M, Bhat K, Musmade P, Surulivelrajan M,

Karthikeyan K, Udupa N. Simultaneous determination of pioglitazone

and glimepiride in bulk drug and pharmaceutical dosage form by RP-

HPLC method. Pak J Pharm Sci 2008;21:4215.

Suresh S, Shivakumar H, Kumar G. Effect of β-cyclodextrin complexation

on solubility and dissolution rate of carbamazepine from tablets. Indian

J Pharm Sci 2006;68: 301-307.

Talegaonkar S, Khan A, Khar R, Ahmad F, Khan Z. Development and

characterization of paracetamol complexes with hydroxypropyl-β-

cyclodextrin. Iranian J Pharm Res 2007;6:95-9.

Jug M, Becirevic-Lacan M. Influence of hydroxypropyl-β-cyclodextrin

complexation on piroxicam release from buccoadhesive tablets. Eur J

Pharm Sci 2004;21:251-60.